Ligand-modified homologous targeted cancer cell membrane biomimetic nanostructured lipid carriers for glioma therapy
The main treatment measure currently used for glioma treatment is chemotherapy; the biological barrier of solid tumors hinders the deep penetration of nanomedicines and limits anticancer therapy. Furthermore, the poor solubility of many chemotherapeutic drugs limits the efficacy of antitumor drugs. Therefore, improving the solubility of chemotherapeutic agents and drug delivery to tumor tissues through the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) are major challenges in glioma treatment. Nanostructured lipid carriers (NLCs) have high drug loading capacity, high stability, and high in vivo safety; moreover, they can effectively improve the solubility of insoluble drugs. Therefore, in this study, we used solvent volatilization and ultrasonic melting methods to prepare dihydroartemisinin nanostructured lipid carrier (DHA-NLC). We further used the glioma C6 cancer cell (CC) membrane to encapsulate DHA-NLC owing to the homologous targeting mechanism of the CC membrane; however, the targeting ability of the CC membrane was weak. We accordingly used targeting ligands for modification, and developed a bionanostructured lipid carrier with BBB and BBTB penetration and tumor targeting abilities. The results showed that DHA-loaded NGR/CCNLC (asparagine-glycine-arginine, NGR) was highly targeted, could penetrate the BBB and BBTB, and showed good anti-tumor effects both in vitro and in vivo, which could effectively prolong the survival time of tumor-bearing mice. Thus, the use of DHA-loaded NGR/CCNLC is an effective strategy for glioma treatment and has the potential to treat glioma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Drug delivery - 28(2021), 1 vom: 12. Dez., Seite 2241-2255 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Mengyu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.01.2022 Date Revised 20.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/10717544.2021.1992038 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332090450 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332090450 | ||
| 003 | DE-627 | ||
| 005 | 20231225214858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10717544.2021.1992038 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM332090450 | ||
| 035 | |a (NLM)34668811 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Mengyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ligand-modified homologous targeted cancer cell membrane biomimetic nanostructured lipid carriers for glioma therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.01.2022 | ||
| 500 | |a Date Revised 20.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The main treatment measure currently used for glioma treatment is chemotherapy; the biological barrier of solid tumors hinders the deep penetration of nanomedicines and limits anticancer therapy. Furthermore, the poor solubility of many chemotherapeutic drugs limits the efficacy of antitumor drugs. Therefore, improving the solubility of chemotherapeutic agents and drug delivery to tumor tissues through the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) are major challenges in glioma treatment. Nanostructured lipid carriers (NLCs) have high drug loading capacity, high stability, and high in vivo safety; moreover, they can effectively improve the solubility of insoluble drugs. Therefore, in this study, we used solvent volatilization and ultrasonic melting methods to prepare dihydroartemisinin nanostructured lipid carrier (DHA-NLC). We further used the glioma C6 cancer cell (CC) membrane to encapsulate DHA-NLC owing to the homologous targeting mechanism of the CC membrane; however, the targeting ability of the CC membrane was weak. We accordingly used targeting ligands for modification, and developed a bionanostructured lipid carrier with BBB and BBTB penetration and tumor targeting abilities. The results showed that DHA-loaded NGR/CCNLC (asparagine-glycine-arginine, NGR) was highly targeted, could penetrate the BBB and BBTB, and showed good anti-tumor effects both in vitro and in vivo, which could effectively prolong the survival time of tumor-bearing mice. Thus, the use of DHA-loaded NGR/CCNLC is an effective strategy for glioma treatment and has the potential to treat glioma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Nanostructured lipid carriers | |
| 650 | 4 | |a biomimetic drug-delivery system | |
| 650 | 4 | |a blood–brain barrier | |
| 650 | 4 | |a cancer cell membranes | |
| 650 | 4 | |a gliomas | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Artemisinins |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Membrane Lipids |2 NLM | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a asparagine-glycine-arginine |2 NLM | |
| 650 | 7 | |a artenimol |2 NLM | |
| 650 | 7 | |a 6A9O50735X |2 NLM | |
| 700 | 1 | |a Cui, Yuexin |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Wenyan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Yueyue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Mingrui |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yingzi |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Chunsheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug delivery |d 1996 |g 28(2021), 1 vom: 12. Dez., Seite 2241-2255 |w (DE-627)NLM09361134X |x 1521-0464 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2021 |g number:1 |g day:12 |g month:12 |g pages:2241-2255 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10717544.2021.1992038 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2021 |e 1 |b 12 |c 12 |h 2241-2255 | ||